Cebranopadol
Acute Pain
Phase 3Active
Key Facts
About Tris Pharma
Tris Pharma is a commercial-stage biopharmaceutical company with a dual focus on innovative CNS therapeutics and generic drugs. Its core innovation is the LiquiXR® extended-release liquid technology platform, which has generated a portfolio of approved ADHD medications and a pipeline of novel candidates, including the late-stage dual NOP-MOP agonist cebranopadol for pain. The company operates as a private entity with over 500 employees, utilizing partnerships and its commercial infrastructure to advance its mission of solving intractable therapeutic challenges.
View full company profileTherapeutic Areas
Other Acute Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| OLINVYK (oliceridine) | Trevena | Approved |
| GRC 27864 | glenmark | Phase 2 |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical or Phase 1 |
| VX-548 | Vertex Pharmaceuticals | Phase 3 |
| Maxigesic® Oral | AFT Pharmaceuticals | Approved |